Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Enrolling by invitation Phase 2 Interventional

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

ClinicalTrials.gov ID: NCT04093570

Public ClinicalTrials.gov record NCT04093570. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Extension study to provide ongoing long-term treatment with ASTX727 for participants who were benefitting from ASTX727 treatment in a previous Taiho (formerly Astex)-sponsored clinical study of ASTX727 (including, but not limited to ASTX727-01 \[NCT02103478\], ASTX727-02 \[NCT03306264\], ASTX727-04 \[NCT03813186\]), ASTX727-06 \[NCT04093570\] food effect substudy, ASTX727-17 \[NCT04953897\], and ASTX727-18 \[NCT04953910\] to obtain long-term safety information. The purpose of the Food Effect Substudy was to evaluate the pharmacokinetics (PK) and safety of decitabine and cedazuridine when ASTX727 was given under fed (high-calorie/high-fat meal or low-calorie/low-fat meal) versus fasted conditions. Food Effect Substudy has now completed.

Study identification

NCT ID
NCT04093570
Recruitment status
Enrolling by invitation
Study type
Interventional
Phase
Phase 2
Lead sponsor
Taiho Oncology, Inc.
Industry
Enrollment
332 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 29, 2019
Primary completion
Dec 30, 2027
Completion
Dec 30, 2027
Last update posted
Jul 27, 2026

2019 – 2027

United States locations

U.S. sites
21
U.S. states
14
U.S. cities
17
Facility City State ZIP Site status
Compassionate Care Research Group Fountain Valley California 92708
Boca Raton Clinical Research Plantation Florida 33322
The University of Chicago Medical Center Chicago Illinois 60637
The Sidney Kimmel Comprehensive Cancer Center at John Hopkins Baltimore Maryland 21231
Cancer and Hematology Centers for Western Michigan Grand Rapids Michigan 49503
Mayo - Rochester Rochester Minnesota 55905
Hackensack Medical Center - 06 FE Study Hackensack New Jersey 07601
Hackensack Medical Center Hackensack New Jersey 07601
Rosewell Park Cancer Institute Buffalo New York 14263
Roswell Park Cancer Institute - 06 FE Study Buffalo New York 14263
Gabrail Cancer Center Research - 06 FE Study Canton Ohio 44718
Gabrail Cancer Center Research Canton Ohio 44718
Oregon Health and Science University Portland Oregon 92739
Charleston Hematology Oncology Associates Charleston South Carolina 29414
Vanderbilt - Ingram Cancer Center Nashville Tennessee 37232
Baylor Scott White University Medical Center Dallas Texas 75246
University of Texas Southwestern Medical Center Dallas Texas 75390
The University of Texas MD Anderson Cancer Center Houston Texas 77030
May Cancer Center San Antonio Texas 78229
Kadlec Clinic Hematology and Oncology Kennewick Washington 99336
Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04093570, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 27, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04093570 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →